Background: The predictive role of HER-2 in node-positive breast cancer patients receiving CMF or an anthracycline-based adjuvant therapy remains unclear. In addition, topo-isomerase II alpha (topo I la), as the cellular target of anthracyclines, might have value as a predictive marker.
Introduction
In the last seven years it has been suggested that HER-2 positive node-positive breast cancer patients might derive the largest benefit from an anthracycline-based adjuvant therapy [1] [2] [3] [4] [5] .
The first study formulating this hypothesis was published in 1994 by the CALGB group and later updated [1, 2] . In this retrospective analysis, primary tumor samples from 994 of the 1572 patients entered into the prospective clinical trial were collected and evaluated for HER-2 overexpression by immunohistochemistry (IHC) and polymerase chain reaction. In the clinical trial, node-positive breast cancer patients were randomly allocated to one of the three treatment arms consisting of the cyclophosphamide-doxorubicinfluorouracil combination (CAF), delivered with a different dose-intensity in each of the study arms [3] . In the whole study population, the most intensive and the moderately intensive CAF regimens were equally active and more effective than the low dose regimen, while the most intensive CAF proved to be the most active treatment in the subgroup of HER-2 positive patients [1] [2] [3] .
In a second study reported in 1998, the US intergroup presented the results of a retrospective analysis based on a prospective randomized trial in which nodepositive post-menopausal patients were treated with tamoxifen alone or CAF plus tamoxifen, the latter given concomitantly or after adjuvant chemotherapy [4] . Primary tumor samples were collected for 595 patients, corresponding to 40% of the prospective study population. HER-2 was evaluated by IHC. The subgroup of HER-2 positive patients derived the largest benefit when CAF was combined with tamoxifen, while no differences in disease-free survival between the hormonoand the chemo-hormonotherapy arms were reported in HER-2 negative patients.
Although these two studies have paved the way for the evaluation of HER-2 as a potential predictive marker for an anthracycline-based therapy, neither of them can lead to firm conclusions because of the lack of a non-anthracycline containing chemotherapy regimen in the CALGB study [1, 2] and of a chemotherapy treatment in the control arm of the US intergroup trial [4] .
In 1998, the NSABP presented the results of two retrospective studies [5, 6] investigating HER-2 as a potential predictive marker for anthracyclines in the adjuvant therapy of node-positive breast cancer. In the first of the two studies [5] , pre-cut unstained slides or hematoxylin-eosin sections were available for 638 of the 682 patients entered in the prospective trial. HER-2 was evaluated by IHC using the so called cocktail technique, which consists in the concomitant staining of the tumor tissue with a monoclonal (TAB-250) and a polyclonal (pAbl) antibody.
In the clinical study, eligible patients were randomized in two different treatment arms consisting of melphalanfluorouracil (PF) or the same regimen plus doxorubicin (PAF). After a mean time on study of 13.5 years, the PAF regimen turned out to be significantly more active than PF in terms of disease-free survival (DFS) and overall survival (OS) in the subgroup of HER-2 positive tumors. No benefit was observed following the addition of doxorubicin in HER-2 negative patients. In this study an interaction test, formally investigating the hypothesis of HER-2 as a predictive marker, was performed and disclosed a statistically significant interaction between doxorubicin and HER-2 overexpression as far as DFS was concerned. The implications of this trial's results in the clinical practice are not immediate, because neither PF nor PAF regimens can be considered appropriate adjuvant therapies in breast cancer patients nowadays.
The most recent of the two NSABP studies tested the same hypothesis by evaluating HER-2 in a series of 2034 of 2295 patients entered in a randomized trial comparing CMF with AC and with AC followed by CMF in node-positive breast cancer [6] . As in the previous NSABP study, HER-2 evaluation was performed by the IHC cocktail on pre-cut unstained slides or hematoxylineosin sections. The AC regimen was more active than CMF in HER-2 positive patients, while equivalence between the two adjuvant therapies was observed in the HER-2 negative subgroup. Nevertheless, statistical significance was not reached when an interaction test was performed.
In the present article, we report the results of our study investigating HER-2 as a potential predictive marker for anthracycline-based therapies. Our retrospective analysis is based on a prospective randomized trial comparing CMF with epirubicin plus cyclophosphamide in the adjuvant treatment of node-positive breast cancer [7] . The two differences existing between the present study and the previously reported studies are: 1) HER-2 has been evaluated by IHC using various antibodies. The interaction between this marker and treatment efficacy has been evaluated according to the antibodies which have been used in the assay. 2) Topo I la expression has also been investigated because this marker might play an important role in determining the sensitivity of breast cancer to an anthracycline-based therapy. Topo 11 a, indeed, is the target enzyme for anthracyclines, and in-vitro data suggest that there is a direct correlation between the sensitivity to anthracyclines and the level of topo Ha expression in the nucleus [8, 9] . Interestingly, HER-2 and topo II genes are located close to each other in chromosome 17 ql2-q21, and they can both be amplified simultaneously in breast cancer [10, 11] . In addition, it has been shown that HER-2 positive tumors display higher levels of the topo I la protein than HER-2 negative tumors, thus suggesting that HER-2 overexpression might be a surrogate marker of sensitivity to anthracyclines [12, 13] .
Patients and methods

Clinical study
The prospective clinical trial on which the present study is based has already been presented, and detailed results have recently been submitted for publication [7] . In brief, pre-and postmenopausal patients aged $ 70 years old, with radically-resected, histologically confirmed, node-positive breast cancer, were randomly allocated to one of the following treatment arms: a) CMF q 4 wks x 6 cycles (oral cyclophosphamide version); b) EC x 8 cycles (epirubicin 60 mg/m 2 dl, cyclophosphamide 500 mg/m 2 i.v. dl, q 3 wks); c) HEC x 8 cycles (epirubicin 100 mg/m 2 dl, cyclophosphamide 830 mg/m 2 l v. dl, q 3 wks). The total treatment duration was 24 weeks in the three treatment arms. Patients were centrally randomized at the operational office of the Chemotherapy Unit, Jules Bordet Institute, Brussels, and stratified according to the participating institution, number of histologically-positive axillary nodes, and menopausal status After the end of chemotherapy, postmenopausal patients with estrogen receptor positive or unknown tumors received tamoxifen 40 mg/day for five years. Loco-regional radiotherapy was performed at the end of chemotherapy in all patients treated with breast-conserving surgery, and in mastectomy-treated patients, according to specific radiotherapy guidelines from each participating center. The primary end-point of this prospective randomized trial was to compare CMF with HEC in terms of event-free survival (EFS). A secondary end-point was to compare the EFS of the two different anthracycline-based treatment groups
Predictive markers study
Tumor samples collection
A list of all patients entered into the clinical study was submitted to each participating center. Each center had to provide the operational office with one paraffin-embedded sample of the primary tumor. Samples were sent by the participating center to the operational office by conventional mail. Once samples were received, they were classified and stored at room temperature until the predictive markers analysis was carried out.
HER-2 evaluation by immunohistochemislry
The evaluation of this marker was carried out at the Pathology Department of the Jules Bordet Institute, Brussels. HER-2 was evaluated by IHC with different antibodies (Abs).
In a first analysis, 4D5 (Genentech, South San Francisco, California) and CB-ll (Biogenex, San Ramon, California) monoclonal Abs have been used according to the following procedures: sections from paraffin-embedded blocks routinely fixed in neutral buffered formalin or bouin were cut on poly-L-lysine-coated slides. The slides were dewaxed and rehydrated. For the antibody 4D5 (dilution 1/100), the slides were pretreated with a 0,4 pepsine solution (HC1 O,1N) at 37 °C for 10 min, before the incubation with the primary antibody (overnight at 4 °C). The slides were incubated at room temperature with the secondary antibody and with the avidin-biotin complex (ABC, Vector) for 30 min each.
For the antibody CB1I (dilution 1/40), the sections were stained using the Ventana Nexes System (Ventana Medical Systems, Tucson, Arizona). Briefly, after a 30 min incubation at 37 °C with the primary antibody, sections were incubated for 10 min at 37° C with the biotinylated secondary antibody and then with avidin-peroxydase for the same time. No antigen retrieval procedures were performed with the CBII mAb. The chromogen was the 3'-3 diaminobenzidine for both 4D5 and CB11 mAbs. All the products needed for these steps were included in the DAB detection kit provided by the manufacturer The slides were then counterstained with Meyer's hematoxylin, dehydrated and mounted.
In a second analysis, motivated by the low percentage (12%) of HER-2 positive tumors identified after the first analysis, sections were incubated with the cocktail of two different Abs from Zymed Laboratories (San Francisco, California): theTAB-250 monoclonal Ab (dilution 1/40) and the p-Abl polyclonal serum (dilution 1/150). The IHC procedures for this second HER-2 evaluation, also known as the cocktail technique, have been described by Paik et al. [13] . In our assay, sections were stained with the Ventana Nexes System, as described for CBI I mAb. Slides were pretreated with tampone citrate (pH 7, microwave oven 600 w, for 5 min for 4 consecutive times). During the second analysis, the pathologist did not know the HER-2 status reported on the same samples after the first analysis.
All slides were read by one pathologist (DL), who scored the evaluated samples according to the percentage of tumor cells with positive staining (0 = no positive cells, 1 = > 1% and <25%, 2 = > 25% and < 50%, 3 = > 50% and < 75%, 4 = > 75%) At this point, the pathologist was blinded with regard to the correspondent treatment arm and clinical outcome for each evaluated sample.
A cut-off to classify samples as HER-2 positive or negative was established. The cut-off value had been decided arbitrarily before correlating the HER-2 status with treatment efficacy. In the first analysis, tumors were defined HER-2 positive if ^ 1% of cells showed a definite staining with CB-ll and/or 4D5 Abs. In the second analysis tumors were classified HER-2 positive if >1% of cells stained positively with the cocktail of TAB 250 and p-Abl. All cases showing cytoplasmic staining were classified as HER-2 unknown. Only the invasive component of the tumor was evaluated.
HER-2 evaluation by fluorescence in situ hybridization (FISH)
The evaluation of HER-2 status by FISH was carried out at the pathology department of the Jules Bordet Institute.
I) Tissue specimens and slide preparation
Four-micron sections were cut from archival tissue which had been fixed in buffered formalin and embedded in paraffin. Sections were placed on Superfrost Plus slides (Menzel-Glaser, Germany). Slidemounted tissue sections were then baked overnight at 65 °C and deparaffinated in xylene for 10 min, x 3, followed by immersion in 100% ethanol for 5 min, x 2. Air dried tissue sections were subsequently treated in 0.2 M HCI for 20 min at room temperature, washed x 2 in 2 x SSC (1 x SSC is 0.15 M NaCI, 0.015 M sodium citrate, pH7) for 5 min each and then treated in a solution of I M NaSCN for 30 min at 80 °C Slides were then washed x 2 in 2 x SSC and treated in a solution of pepsin (0.5 mg/ml) in 0.9% NaCI (pH 2) for 10 to 20 min at 37 °C. Following pepsin digestion, tissue sections were washed in 2 x SSC as above and dehydrated in graded alcohol (70%. 90% and 100% ethanol).
2) In situ hybridization (according to the Vysisprotocol)
Slide-mounted tissue sections were denaturated in 70% formamide/ 2 x SSC, pH 7.0 at 74 °C for 5 min and then immersed in 70% ethanol at room temperature. After dehydration through graded alcohols, slides were air dried and warmed at 45 °C. The dual color probe Specturm Orange HER-2/Spectrum Green CEPI7 (PathVysion. cat # 30-161060, Vysis, Downers Grove, Illinois) was then applied (10 ul) on a selected area of the sample (invasive part of the tumor) and sections were coverslipped and sealed with rubber cement. Hybridization was carried out overnight at 37 °C in a moist chamber. Washes were performed at 74 °C for 2 min in 0.2 x SSC/0.3% NP-40. After drying, sections were counterstained with a 4', 6-diamidine 2 phenylindoledihydrochloride (DAPI, Boehringer Mannheim, Germany) antifade solution and analyzed.
3) Fluorescence microscopy and scoring criteria A Leica DMRB epifluorescence microscope equipped with a 100 watt mercury-arc lamp and 40 x and 100 x objectives were used in combination with aTriple bandpass filter (DAPI/FITC/TR1TC). Scanned at low magnification (40 x), at least 60 hybridized nuclei from invasive parts of tissue sections were counted. Amplification was determined as a ratio of the number of HER-2 signals/centromeric 17 signals > 2. A ratio between two and five was qualified as moderate, a ratio of more than five as high. At the time amplification in each sample was evaluated, the pathologist (DG) did not know the HER-2 score reported with IHC.
Topo lla evaluation
This marker was evaluated by the pathology department of the Jules Bordet Institute. The IHC procedures that have been used were as follows: sections from paraffin-embedded blocks routinely fixed in neutral buffered formalin or bouin were cut on poly-L-lysine-coated slides. The slides were dewaxed and rehydrated. After a pretreatment with trypsine (dilution 1/100, for 10 min at 37 °C), the incubation with the primary antibody Topo 11a (clone KiSI, Boerhinger-Manheim, cat No 1742353, dilution 1/100. at 4°C, overnight) was followed by the secondary antibody and avidin-biotin complex (ABC, Vector) for 30 min, each at room temperature. 3'-3 diaminobenzidine was used as a chromogen.
Slides were read by one pathologist (DL). who reported for each case the percentage of tumor cells with positive staining (from 0% to 100%). At this point the pathologist did not know the assigned treatment and corresponding outcome of each case No allocation of each sample in five distinct categories, as done for the HER-2 evaluation, was feasible in this case because the vast majority of samples had a percentage of positive cells ranging between one and twenty-five percent. Accordingly, it was decided to calculate the median percentage of cells with positive staining based on the percentage of positive cells in each evaluated sample, and to use the median value as a cut-off for definition of topo Hot positive and negative tumors. This decision was taken before correlating the topo I la status with treatment efficacy.
All samples showing > 10% (10% = median value) of tumor cells with positive staining were defined as topo I la positive, while samples with < 10% of positive cells were defined as topo I la negative. Tumors with aspecific staining (i.e., staining outside the nucleus) were classified as topo I la unknown. Only the invasive component of the tumor was evaluated
Statistical analysis
Event-free survival (EFS) was defined as the interval elapsed between the date of randomisation and the date of documented disease relapse, second primary or death. EFS distribution was estimated by the Kaplan-Meier method or by using Cox modelling. No overall survival (OS) analysis was done in the subgroup of patients identified by the investigated biological markers because of the low number of events observed in each treatment group.
The patients evaluated in the present retrospective study (predictive markers study) were a subgroup of the study population entered into the prospective clinical trial. To evaluate the representativeness of this subgroup, those factors with prognostic significance in the univanate analysis performed on the 777 patients entered into the clinical study were evaluated and compared in the two distinct groups (i.e.. 296 patients not evaluated in the present study because of the lack of a tumor sample and 481 patients entered into the present study).
The different cohorts of patients identified by HER-2 and topo Ha were examined with regard to differences in the magnitude of treatment effect on patient outcome by calculating the hazard ratio and the correspondent 95% confidence intervals and /"-values for no effect. Hazard ratios were calculated for the following comparisons: HEC vs. CMF, HEC vs. EC and EC vs. CMF. The Cox proportional hazards model was used to adjust the observed treatment effects for the influence of those factors with prognostic significance (P < 0.05) in the univariate analysis performed on 777 patients entered into the clinical trial. The following list of putative prognostic factors for EFS was evaluated in the univariate analysis: age. menopausal status, surgery type, histologic grade, histologic type, tumor clinical size, tumor pathological size, number of involved ipsilateral axillary nodes, estrogen and progesterone receptor status. Surgery type (mastectomy vs. conserving surgery) and number of involved axillary nodes (1-3. > 4) were the only factors with prognostic significance in the univariate analysis. Accordingly, these two factors were introduced into the Cox proportional hazards model to calculate the adjusted hazard ratios. To test the main study hypothesis that the therapeutic benefit from HEC compared to CMF was larger in HER-2 positive than in HER-2 negative patients, as well as larger in topo I la positive than in topo I la negative patients, an interaction term combining treatment arm and HER-2 status (or treatment arm and topo I la status) was added to the Cox proportional hazards model. Its significance was tested using a likelihood ratio test.
Results
Clinical study
Between March 1988 and December 1996, 804 patients were randomized into the clinical study. Twenty-seven patients (3%) were considered ineligible because of lack of adherence to the main eligibility criteria. The allocated treatment for the 777 eligible patients was as follows: CMF, 255 pts; EC, 267 pts; and HEC, 255 pts. Between 41% and 44% of the patients were postmenopausal. Sixty-seven percent, 63% and 64% of the patients were treated with mastectomy in the CMF, EC and HEC arms, respectively. Between 39% and 41% of the patients had four or more involved ipsilateral axillary nodes.
The main patient characteristics were well balanced between the three study arms, and no statistically significant differences in their distribution were found. The median relative dose-intensities were 0.89, 0.95 and 0.90 for CMF, EC and HEC, respectively. The median number of cycles delivered was six for CMF, and eight for both the EC and HEC treatment groups.
At a median study follow-up of 50 months, no differences between HEC and CMF were observed with regard to EFS and OS (EFS: HEC vs. CMF, HR = 0.96, 95% CI: 0.70-1.31, F-value = 0.80; OS: HEC vs. CMF, HR = 0.97, 95% CI: 0.65-1.44, P-value = 0.87). No differences with regard to EFS were observed between HEC and CMF in the subgroup of patients identified according to the following factors: age (<50 or ^50), number of positive axillary nodes (1-3 or ^4), tumor size (pTl or >pTl), ER and PgR status (positive or negative), and histologic grade (1 or 2 or 3) .
The secondary study comparison, between HEC and EC, shows a statistically significant advantage in favour of HEC over EC with regard to EFS and OS (EFS: HEC vs. EC, HR = 0.73, 95% CI: 0.54-0.99, P-value 0.04; OS: HEC vs. EC, HR = 0.69, 95% CI: 0.47-1.00, P-value 0.05).
Predictive markers study
Collection of tumor samples Four hundred eighty-one paraffin-embedded samples of the primary tumor were collected between September 1996 and March 1998, corresponding to 62% of the clinical study population (777 eligible patients). The 481 blocks were collected from 12 of the 14 centers participating in the clinical study; all the centers which entered at least ten patients into the clinical study contributed to the collection of tumor samples. Of the 481 patients entered into the predictive markers study, 160 were treated with CMF and 170 with EC, while the remaining 151 received HEC.
The number of positive axillary nodes and the surgery type (mastectomy vs. conservative treatment) were the only factors with prognostic significance in the univariate analysis performed on the 777 evaluated patients. Fortyone percent and 40% of patients had ^4 positive axillary nodes in the two groups of patients without (n = 296) and with (n -481) available tumor samples, respectively.
The percentages of patients treated with mastectomy were 63% and 66% in the two groups with and without available samples, respectively. These differences are not statistically significant. Accordingly, it is suggested that the population evaluated in the present retrospective analysis is representative of the whole population entered into the clinical trial. Detailed patient characteristics in the two distinct subgroups with and without available tumor samples are reported in Table 1 .
HER-2 overexpression
Results regarding the HER-2 status among the 481 evaluated patients are reported in Table 2 . The first evaluation of HER-2 was done by CB-11 and 4D5. It is worth noting that only 12% of tumors were defined as HER-2 positive, possibly because no antigen retrieval procedures were performed when the CB-11 mAb was used. Afterwards, it was decided to evaluate HER-2 by the cocktail technique, which was supposed to be more sensitive [14] .
As expected, the cocktail technique identified the highest number of HER-2 positive patients. In those samples where the HER-2 status remained unknown, the main reasons were inadequacy of the tumor sample (lack of the invasive component), or cytoplasmic staining. 45 (9) 4D5 and CB-ll Figure 1 describes the results of the EFS comparison between HEC and CMF in the two subgroups of HER-2 positive and negative patients. In this analysis, the HER-2 status has been evaluated by using the CB-ll and 4D5 monoclonal antibodies. It must be emphasized that the number of HER-2 positive patients who received CMF or HEC is fairly limited (37 cases). Nevertheless, the difference in point estimates of the hazard ratios vary: 0.33 favoring HEC in HER-2 positive patients, and 1.16 favoring CMF in HER-2 negative patients. However, statistical significance is not reached in either of the two subgroups, and the confidence intervals for the two hazard ratios overlap. Figure 2 reports the results of the EFS comparison between the same treatment arms when HER-2 is evaluated by the cocktail technique. The interaction reported in Figure 1 between HER-2 and the two adjuvant regimens disappears when HER-2 is evaluated by the cocktail technique. HEC and CMF seem to have comparable efficacy in both HER-2 positive and negative patients. As in the analysis reported in Figure 1 , the number of HER-2 positive patients identified by the cocktail technique is limited and corresponds to sixty-one cases.
Interaction between HER-2 and treatments efficacy a) HEC vs. CMF
To explain the discordance observed in the two analyses, it has been hypothesized that the antibodies used in the IHC assay identified two different groups of HER-2 positive patients. Accordingly, the HER-2 status by CB11 and 4D5 was correlated to the HER-2 status by the cocktail in those patients where both evaluations were available. Among the 78 patients identified as positive by the cocktail technique, 46 were also positive by CB11 and/or 4D5, while the remaining 32 were negative by both CB11 and 4D5. Among the 49 patients evaluated as HER-2 positive by CBll and/or 4D5, only three were HER-2 negative by the cocktail technique. In summary, for the vast majority of the HER-2 positive patients identified by CB-ll and/or 4D5, the cocktail technique confirmed the HER-2 positive status. The cocktail technique identified an additional number of HER-2 positive patients who were negative by CB-ll and4D5.
It has been speculated that the HER-2 positive patients identified only by the cocktail might have a false positive status. To this purpose, HER-2 gene amplification by FISH was evaluated in each sample for both the groups of HER-2 positive cases by CBll and/or 4D5 and the group of HER-2 positive cases by the cocktail only. Results are reported in Table 3 .
Because of tumor sample fixation in bouin, it was not possible to evaluate amplification by FISH in 24 of the 49 HER-2 positive patients by CBH/4D5, and in II of the 32 HER-2 positive patients by the cocktail only. It is worth noting that almost all the patients had amplification when HER-2 was overexpressed according to CBH/4D5 mAbs. In addition, all cases showing amplification had a HER-2 /centromere 17 ratio > 5, suggesting a high level of HER-2 amplification. Conversely, in Table 3 . HER-2 amplification in the two groups of HER-2 positive patients by CBI1 and/or 4D5 and by the cocktail only In these analyses, hazard ratios were adjusted for the number of pathologically involved axillary nodes and the type of surgery.
We can conclude that when HER-2 was evaluated by CB-11 and 4D5 mAbs, there was a trend to an increased efficacy of HEC over EC in HER-2 positive patients, although the same effect was observed to a lesser extent in the HER-2 negative subgroup.
Conversely, the HER-2 evaluation by the cocktail method was even suggesting an increasing efficacy of HEC over EC in HER-2 negative patients. It is worth noting that in 27% of the tumors, topo
Interaction between topo lla. and treatment efficacy a) HEC vs. CMF Figure 3 reports the results of the EFS comparison between HEC and CMF in the two subgroups of topo I la positive and negative patients. About fifty patients per arm were evaluated in this analysis. It may be observed that patients receiving HEC seem to have a better EFS than patients treated with CMF only in the subgroup of topo I la positive tumors. However, no statistical significance was reached with a P-value of 0.13 for the interaction test. It is interesting to observe that, as expected, HEC seems to be more effective than EC in topo Ila positive tumors, while equivalence between the two epirubicinbased regimens seems to be observed in topo Ila negative patients. Nevertheless, this difference in treatment efficacy according to the topo Ila status does not achieve a statistical significance.
c) EC vs. CMF
In the subgroup of topo Ila positive tumors, HR was 1.03, 95% CI: 0.75-1.41, P-value 0.85; in topo Ila negative tumors, HR was 1.09, 95% CI: 0.78-1.54, P-value 0.61; f-value for the interaction test = 0.87.
Discussion
The present study investigates the value of HER-2 and topo Ila in predicting the efficacy of CMF and of an anthracycline-based treatment when these regimens are proposed as adjuvant therapy to node-positive breast cancer patients.
With regard to HER-2, contrasting results have been reported as far as its predictive role is concerned. When the evaluation of HER-2 was done separately by two different monoclonal antibodies (CB11 and 4D5), the results suggested that HER-2 might be a useful tool to select the most effective adjuvant regimen between CMF and an epirubicin-based treatment. Conversely, when the evaluation of HER-2 was performed by the cocktail technique, the previously observed interaction between the marker and treatment efficacy was completely lost.
We believe that there are two different explanations for the reported results: a) the number of patients who have been evaluated is fairly limited. The study had a statistical power of 80% to detect a hazard ratio of 4.5 for the HEC vs. CMF comparison in the subgroup of HER-2 positive patients by CB-11 and/or 4D5 mAbs. More consistent results between the two different analyses might have been found if larger numbers of patients were evaluated; b) while the cocktail technique identified a relevant number of HER-2 positive patients in which no or moderate amplification was reported, the CB-11/4D5 antibodies disclosed a population of HER-2 highly amplified tumors, as shown in Table 3 . In this population, HER-2 seems to have a predictive value as far as the efficacy of an anthracycline-based adjuvant therapy is concerned. This finding supports the results of other studies reporting an interaction between anthracycline efficacy and HER-2 overexpression [1-2, 4-6]. Nevertheless, in view of the difficulties so far encountered in standardizing the HER-2 evaluation, and taking into consideration that all the studies testing HER-2 as a predictive marker have a retrospective design and a limited number of HER-2 positive patients, the use of HER-2 as an established predictive factor in the adjuvant therapy of breast cancer must be discouraged until more convincing evidence becomes available.
This study suggests that topo Ila might be a marker of potential help in selecting those patients who are candidates for an anthracycline-based adjuvant therapy. It is worth noting that when topo Ila was evaluated as a potential predictive marker for identifying patients responsive to an anthracycline-based therapy (HEC vs. CMF), as well as to a dose-intensive epirubicin-cyclophosphamide regimen (HEC vs. EC), results suggested that an interaction between topo Ila levels and the efficacy of the epirubicin-based treatments might exist, although no statistical significance was reached. The main problem in the evaluation of topo Ila as a predictive marker relates to the difficulties encountered in measuring its levels by IHC. In the present study 27% of samples were classified as unknown with regard to the topo-IIa levels, and in most of these cases this was due to an unspecific staining outside the nucleus. In addition, it has been suggested that the determination of topo Ila levels by IHC would be more related to the tumor proliferation rate rather than to the actual levels of topo-IIa overexpression in the nucleus [12, 15] . Fluorescence in situ hybridization (FISH) seems to be a more appropriate technique to properly evaluate topo Ila overexpression and downregulation caused by the gene amplification. It has been reported that this technique allows recognizing topo Ila gene deletion and amplification, and that these gene aberrations are most frequently detected in tumors with HER-2 gene amplification [10, 11] . In addition, it has been shown that breast cancer cells with HER-2 and topo Ila amplification are sensitive to anthracyclines, while HER-2 amplified cells with topo Ha gene deletion are resistant to anthracyclines [11] . In view of the results of the present study, and according to the in vitro data which have been recently reported [10, 11] , the investigation of topo Hoc by FISH seems to be of high priority in future predictive marker studies as far as an anthracycline-based treatment is concerned.
In conclusion, the present study suggests that different results can be observed with regard to the role of HER-2 as a predictive marker according to the antibodies used for its evaluation by immunohistochemistry. However, when HER-2 was evaluated by CB11 and 4D5 mAbs, according to the procedures followed in the present study, a non statistically significant trend was found, supporting the concept that HER-2 could predict the efficacy of an anthracycline-based adjuvant therapy.
Because of the limited statistical power of this analysis, additional investigations are justified. In addition, this study supports the concept that topo Ha might be involved in the determination of tumor responsiveness to an anthracycline-based treatment.
